Nutriband Appoints Navy SEAL Robert J. O’Neill to Advisory Board

Nutriband (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, has appointed Robert J. O’Neill to its Advisory Board. O’Neill brings a distinguished background, having served 16 years in the U.S. Navy, including eight years with the Naval Special Warfare Development Group (SEAL Team Six), and participating in over 400 combat missions. He is also a New York Times best-selling author and a vocal advocate for expanding veterans’ access to emerging health treatments.

In his advisory role, O’Neill will support Nutriband’s executive team on strategy, growth, and execution as the company advances its pipeline of abuse-deterrent transdermal products. The lead product, AVERSA™ Fentanyl, is positioned to become the world’s first and only abuse-deterrent fentanyl patch if approved. This innovative patch incorporates Nutriband’s proprietary AVERSA™ abuse-deterrent technology, which can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more details, visit the full press release at https://ibn.fm/WuoNR.

Nutriband’s efforts are further supported by InvestorWire, a specialized communications platform under the Dynamic Brand Portfolio @ IBN, which provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. This partnership ensures that Nutriband’s developments reach a broad audience of investors and industry stakeholders.